MedTrace Logo

Li-Fraumeni Syndrome Imaging Study

NCT03176836 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-29

No results posted yet for this study

Summary

Li-Fraumeni Syndrome (LFS) is a cancer predisposition disorder in which most affected individuals develop cancer during their lifetime. The majority of LFS patients carry a mutation in a gene called TP53, whose normal function is to control cell growth and prevent cells with damaged DNA from becoming cancerous. There is currently no way to determine when, where or what type of tumour will develop. This project will use novel techniques utilizing magnetic resonance imaging (MRI) to determine how sensitive they are at detecting very small tumors and how specific they are in terms of distinguishing malignant tumors from benign tumors.

Conditions

  • Li-Fraumeni Syndrome

Interventions

DIAGNOSTIC_TEST

Whole body STIR MRI

Standard technique that detects abnormalities related to excess of water in tissues (edema).

DIAGNOSTIC_TEST

DW-MRI

MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.

DIAGNOSTIC_TEST

PET-MRI

MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.

Sponsors & Collaborators

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Andrea Doria, MD · The Hospital for Sick Children

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-20
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03176836 on ClinicalTrials.gov